How many Skyrizi biosimilars are approved?

Drug Landscape tracks 1 approved Skyrizi biosimilars across global regulators. 0 additional applications are filed and 2 are in Phase 3.

Is Skyrizi still patent-protected?

All tracked patents on Skyrizi have expired in tracked territories.

What is a biosimilar?

A biosimilar is a biological medicine highly similar to an already-approved reference biologic (the originator), with no clinically meaningful differences in safety, purity, or potency. Approved via abbreviated regulatory pathways once the originator's data exclusivity and patents expire.

Last reviewed 2026-06-09 · How we verify

Skyrizi biosimilars

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Complete Skyrizi (RISANKIZUMAB) biosimilar landscape: 1 approved biosimilars, 0 filed, 2 in Phase 3. Sponsor, approval status, first approval date, and patent timeline for the originator.

1 approved 0 filed 2 Phase 3 All key patents expired

About Skyrizi

Skyrizi (RISANKIZUMAB) — originally marketed by AbbVie. Class: Interleukin-23 Antagonist [EPC]. Target: Interleukin-23 subunit alpha. Area: Immunology. First approved 2019-01-01.

Approved biosimilars (1)

Biosimilar	Sponsor	Phase	First approval	Country
Risankizumab (RISA)	Caja Costarricense de Seguro Social	marketed

Filed biosimilars under regulatory review (0)

No biosimilars currently under regulatory review.

Phase 3 biosimilars (2)

Biosimilar	Sponsor	Phase	First approval	Country
risankizumab SC	AbbVie	phase 3
risankizumab IV	AbbVie	phase 3

Originator patent timeline

Active patents (0)

No active patents tracked.

Expired patents (0)

No expired patents tracked.

Subscribe to biosimilar updates

Every regulatory action on Skyrizi or any of its biosimilars:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing